



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/892,485	06/28/2001	Mitsuko Ishihara	210577US0SRD	3202

22850 7590 08/27/2002

OBLON SPIVAK MCCLELLAND MAIER & NEUSTADT PC  
FOURTH FLOOR  
1755 JEFFERSON DAVIS HIGHWAY  
ARLINGTON, VA 22202

EXAMINER

CHAKRABARTI, ARUN K

ART UNIT PAPER NUMBER

1634

DATE MAILED: 08/27/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/892,485

Applicant(s)

ISHIHARA ET AL.

Examiner

Arun Chakrabarti

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 12 August 2002.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-4 and 6-28 is/are pending in the application.
- 4a) Of the above claim(s) 11-14 and 21-23 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-4, 6-10, 15-20 and 24-28 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

Art Unit: 1634

## DETAILED ACTION

### *Specification*

1. Claim 5 has been canceled without prejudice towards further prosecution and new claims 24-28 have been added.

### *Claim Rejections - 35 USC § 102*

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

3. Claims 1-4 and 24 are rejected under 35 U.S.C. 102 (e) as being anticipated by Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999).

Lonial et al teach a method of detecting an endocrine disrupting action of a test substance (Abstract), comprising:

a) culturing a cell having a sensitivity to an endocrine hormone in a first culture system in which endocrine hormone and the test substance are present (Claim 12 and column 10, line 65 to column 12, line 16);

b) determining the presence or absence of an endocrine disrupting action of the test substance by comparing a first gene expression pattern obtained from the cell of the first culture

Art Unit: 1634

system with a second gene expression pattern expressed by a cell having a sensitivity to the endocrine hormone (Claim 12 and column 10, line 65 to column 12, line 16 and Figure 3).

Lonial et al inherently teach a method comprising a second, third and fourth culture system in which presence and absence of endocrine hormone and test substances are modulated (Claim 12 and column 10, line 65 to column 12, line 16 and Figure 3).

***Claim Rejections - 35 USC § 103***

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CAR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103© and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Art Unit: 1634

5. Claims 7, 9, 15-17, 26, and 28 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Gillies et al. (U.S. Patent 4,663,281) (May 5, 1987).

Lonial et al teach a method of claims 1-4 and 24 as described above.

Lonial et al do not teach a method, wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation.

Gillies et al teach a method, wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation (Figures 2, 7, and 8).

Lonial et al do not teach a method, wherein comparison of the gene expression patterns are made by hybridizing gene groups, and subtracting unhybridized genes.

Gillies et al teach a method, wherein comparison of the gene expression patterns are made by hybridizing gene groups, and subtracting unhybridized genes (Figures 7-8).

Lonial et al do not teach a method, wherein glycoprotein is expressed in cells.

Gillies et al teach a method, wherein glycoprotein is expressed in cells (Column 5, lines 30-37).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands

Art Unit: 1634

obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al, since Gillies et al states, "More specifically, the invention relates to a method of exploiting the genetic mechanism of certain types of eukaryotic cells to produce relatively large quantities of a protein of interest or its precursor (Column 1, lines 11-15)" Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Gillies et al, of an invention which relates to a method of exploiting the genetic mechanism of certain types of eukaryotic cells to produce relatively large quantities of a protein of interest or its precursor and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

Art Unit: 1634

6. Claims 8, 10, and 27 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Pearson et al. (U.S. Patent 5,916,779) (June 29, 1999).

Lonial et al teach a method of claims 1-4, and 24 as described above.

Lonial et al do not teach a method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern.

Pearson et al teach a method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern (Abstract, Claim 1 and Figure 1 and Column 2, lines 13-56).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern of Pearson et al in the method of Lonial et al, since Pearson et al states, "Amplification of RNA and DNA targets is often desirable for diagnostic application of amplification technologies, as this gives the greatest number of amplifiable targets per sample. , and as a result, the greatest diagnostic sensitivity. Amplification of RNA targets is also useful for diagnostic monitoring of RNA-related conditions such as certain viremias, up regulation of cancer genes, etc. Amplification of RNA targets is referred to as "reverse transcription amplification", the best known method being reverse transcription PCR.(Column 2, lines 17-26)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the

Art Unit: 1634

development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein RNA is recovered and subjected to RT PCR to detect a band specific to gene expression pattern of Pearson et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Pearson et al, of an invention which provides amplification of RNA targets by the best known method reverse transcription PCR useful for diagnostic monitoring of RNA-related conditions such as certain viremias, up regulation of cancer genes, etc. and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

7. Claims 6 and 25 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Comoglio et al. (U.S. Patent 6,030,949) (February 29, 2000) further in view of Cubicciotti (U.S. Patent 6,287,765 B1) (September 11, 2001).

Lonial et al teach a method of claims 1-4, and 24 as described above.

Lonial et al do not teach a method, wherein cell is Neuro2a.

Comoglio et al. teach a method, wherein cell is Neuro2a (Examples 2 and 3).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method, wherein cell is Neuro2a of Comoglio et al in the method of Lonial et al, since Comoglio et al states, "The invention refers to



Art Unit: 1634

transduced cells for use in the therapy of the above mentioned pathologies (Column 2, lines 6-8)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al. in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Comoglio et al, of an invention which refers to transduced cells for use in the therapy of certain neurodegenerative pathologies and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

8.. Claims 18 and 19 are rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Gillies et al. (U.S. Patent 4,663,281) (May 5, 1987) further in view of Comoglio et al. (U.S. Patent 6,030,949) (February 29, 2000) further in view of Cubicciotti (U.S. Patent 6,287,765 B1) (September 11, 2001)..

Lonial et al. in view of Gillies et al teach the method of claims 1-4, 7, 9, and 15-17 as described above.

Art Unit: 1634

Lonial et al. in view of Gillies et al do not teach a method, wherein cell is Neuro2a.

Comoglio et al. teach a method, wherein cell is Neuro2a (Examples 2 and 3).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method, wherein cell is Neuro2a of Comoglio et al in the method of Lonial et al in view of Gillies et al, since Comoglio et al states, "The invention refers to transduced cells for use in the therapy of the above mentioned pathologies (Column 2, lines 6-8)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein glycoprotein is expressed in cells and wherein comparison of the gene expression patterns are made by comparing bands obtained by subjecting a gene group contained in each of gene expression patterns to electrophoretic separation of Gillies et al in the method of Lonial et al. in view of Gillies et al in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Comoglio et al, of an invention which refers to transduced cells for use in the therapy of certain neurodegenerative pathologies and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

Art Unit: 1634

Lonial et al. in view of Gillies et al. further in view of Comoglio et al. do not teach a method, wherein endocrine hormone is triiodothyronine.

Cubicciotti teaches a method, wherein endocrine hormone is triiodothyronine (Column 182, lines 18-46).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute a method, wherein endocrine hormone is triiodothyronine of Cubicciotti in the method of Lonial et al. in view of Gillies et al. further in view of Comoglio et al., since Cubicciotti states, "Examples of analytes for which such a complex is useful include, but are not limited to, hormones such as thyroxine and triiodothyronine (Column 182, lines 28-30)". Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein endocrine hormone is triiodothyronine of Cubicciotti in the method of Lonial et al. in view of Gillies et al. further in view of Comoglio et al., in order to improve the process for detecting an endocrine disrupting action of a test substance and in order to achieve the express advantages, as noted by Cubicciotti, of triiodothyronine which refers to examples of equivalent useful analyte complex and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

Art Unit: 1634

9. Claim 20 is rejected under 35 U.S.C. 103 (a) over Lonial et al. (U.S. Patent 6,001,560) (December 14, 1999) in view of Gillies et al. (U.S. Patent 4,663,281) (May 5, 1987) further in view of Makari (U.S. Patent 4,752,471).

Lonial et al. in view of Gillies et al teach the method of claims 1-4, 7, 9, and 15-17 as described above including the electrophoresis.

Lonial et al. in view of Gillies et al do not teach a method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain.

Makari teaches a method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain (Claim 5).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to combine and substitute the method, wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain. of Makari in the method of Lonial et al in view of Gillies et al., since Makari states, "The present invention relates to cancer detection preparations, their administrations and their methods of manufacture (Column 1, lines 28-30)." Moreover, Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)". By employing scientific reasoning, an ordinary practitioner would have been motivated to combine and substitute the method wherein protein is recovered from the glycoprotein by cutting off the polysaccharide chain. of Makari in the method of Lonial et al. in view of Gillies et al in order to improve the process for detecting an endocrine

Art Unit: 1634

disrupting action of a test substance and in order to achieve the express advantages, as noted by Makari, of an invention which relates to cancer detection preparations, their administrations and their methods of manufacture and also in order to achieve the express advantages, as noted by Lonial et al, which would facilitate the search for hormone agonists and antagonists by the development of a fast and effective in vitro screening system.

***Response to Amendment***

10. In response to amendment, all previous 112 (second paragraph) rejections are hereby withdrawn. However, all 102(e) and 103(a) rejections are hereby properly maintained.

***Response to Arguments***

11. Applicant's arguments and declaration filed on August 12, 2002 have been fully considered but they are not persuasive.

Applicant argues that Lonial et al. reference does not teach the detection of endocrine disrupting action of the claimed invention. Applicant argues that the word "endocrine disrupting action" was not found in Lonial reference. Applicant argues that because Lonial has a preferred embodiment of induction of gene expression by a hormone, Lonial is limited to the preferred embodiment. This argument is not persuasive. As MPEP 2123 states "Disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. In re Susi, 169 USPQ 423 (CCPA 1971)." MPEP 2123 also states "

Art Unit: 1634

A reference may be relied upon for all that it would have reasonably suggested to one having ordinary skill in the art, including nonpreferred embodiments. *Merck & Co. v. Biocraft Laboratories*, 10 USPQ2d 1843 (Fed. Cir. 1989).” It is clear that simply because Lonial has a preferred embodiment, this embodiment does not prevent the reference from suggesting broader embodiments in the disclosure and that this does not constitute a teaching away. Although Lonial reference uses hormone IFN-gamma to induce the gene expression, the property of “endocrine disrupting action” is inherently present (especially when presence or absence of human IFN-gamma antagonist is detected by detecting the reduced gene expression) in this chemically and structurally identical molecule. For example, Lonial teaches that such antagonists of IFN-gamma, which are inherently causing “endocrine disrupting action” are detected by comparison of gene expression levels (Column 3, lines 20-25 and claims 12-17). Moreover, MPEP 2111 states, “Claims must be given their broadest reasonable interpretation. During patent examination, the pending claims must be “given the broadest reasonable interpretation consistent with the specification”. Applicant always has the opportunity to amend the claims during prosecution and broad interpretation by the examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than it is justified. *In re Prater*, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550-51 (CCPA 1969)”. In this case, any hormone antagonist can be considered as a reagent which can inherently cause “endocrine disrupting action”.

In response to applicant's argument that the Lonial references fail to show certain features of applicant's invention, it is noted that the features upon which applicant relies (i.e., the presence

Art Unit: 1634

of natural endocrine hormone) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

In response to applicant's arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). Applicant also argues that there is no motivation to combine the references. This argument is not persuasive, especially in the presence of strong motivation provided by Lonial et al., as Lonial et al provide further motivation as Lonial et al state, "The search for such agonists and antagonists would be facilitated by the development of a fast and effective in vitro screening system (Column 2, lines 29-31)" This logic is applicable to all other references cited in the 103(a) rejection.

In view of the response to arguments, all previous 102(e) and 103(a) rejections are hereby properly maintained.

### ***Conclusion***

12. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO**

Art Unit: 1634

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703) 306-5818.


The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-7401.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group analyst Chantae Dessau whose telephone number is (703) 605-1237

Arun Chakrabarti,  
Patent Examiner,

August 21, 2002

  
W. Gary Jones  
Supervisory Patent Examiner  
Technology Center 1600